Skip to main content

MKO Troche and Alcohol/Food Interactions

There are 4 alcohol/food/lifestyle interactions with MKO Troche (ketamine / midazolam / ondansetron).


ketamine food

Moderate Food Interaction

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of ketamine. Use in combination may result in additive central nervous system (CNS) depression and/or impairment of judgment, thinking, and psychomotor skills.

GENERALLY AVOID: Coadministration of oral ketamine with grapefruit juice may significantly increase the plasma concentrations of S(+) ketamine, the dextrorotatory enantiomer of ketamine. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. When a single 0.2 mg/kg dose of S(+) ketamine was administered orally on study day 5 with grapefruit juice (200 mL three times daily for 5 days) in 12 healthy volunteers, mean S(+) ketamine peak plasma concentration (Cmax) and systemic exposure (AUC) increased by 2.1- and 3.0-fold, respectively, compared to administration with water. In addition, the elimination half-life of S(+) ketamine increased by 24% with grapefruit juice, and the ratio of the main metabolite norketamine to ketamine was decreased by 57%. The pharmacodynamics of ketamine were also altered by grapefruit juice. Specifically, self-rated relaxation was decreased and performance in the digit symbol substitution test was increased with grapefruit juice, but other behavioral or analgesic effects were not affected.

MANAGEMENT: Patients receiving ketamine should not drink alcohol. Caution is advised when ketamine is used in patients with acute alcohol intoxication or a history of chronic alcoholism. Following anesthesia with ketamine, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination, such as driving or operating hazardous machinery, for at least 24 hours and until they know how the medication affects them. Patients treated with oral ketamine should also avoid consumption of grapefruit and grapefruit juice during treatment. Otherwise, dosage reductions of oral ketamine should be considered.


  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Ketalar (ketamine)." JHP Pharmaceuticals (2009):
  4. Peltoniemi MA, Saari TI, Hagelberg NM, Laine K, Neuvonen PJ, Olkkola KT "S-ketamine concentrations are greatly increased by grapefruit juice." Eur J Clin Pharmacol 68 (2012): 979-86
View all 4 references

midazolam food

Moderate Food Interaction

Consumer information for this interaction is not currently available.

GENERALLY AVOID: The pharmacologic activity of oral midazolam, triazolam, and alprazolam may be increased if taken after drinking grapefruit juice. The proposed mechanism is CYP450 3A4 enzyme inhibition. In addition, acute alcohol ingestion may potentiate CNS depression and other CNS effects of many benzodiazepines. Tolerance may develop with chronic ethanol use. The mechanism may be decreased clearance of the benzodiazepines because of CYP450 hepatic enzyme inhibition. Also, it has been suggested that the cognitive deficits induced by benzodiazepines may be increased in patients who chronically consume large amounts of alcohol.

MANAGEMENT: The manufacturer recommends that grapefruit juice should not be taken with oral midazolam. Patients taking triazolam or alprazolam should be monitored for excessive sedation. Alternatively, the patient could consume orange juice which does not interact with these drugs. Patients should be advised to avoid alcohol during benzodiazepine therapy.


  1. "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn (2002):
  2. "Product Information. Valium (diazepam)." Roche Laboratories (2002):
  3. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn (2001):
  4. "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4
  5. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8
  6. Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31
  7. Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77
View all 7 references

High Blood Pressure (Hypertension)

Major Potential Hazard, Moderate plausibility

ketamine - hypertension

The use of ketamine is contraindicated in patients whom a significant elevation of blood pressure would constitute a serious hazard. It is recommended to monitor cardiac function continually during a procedure in patients with hypertension or cardiac decompensation.


  1. "Product Information. Ketalar (ketamine)." JHP Pharmaceuticals (2009):


Moderate Potential Hazard, High plausibility

benzodiazepines - obesity

The plasma half-lives of benzodiazepines may be prolonged in obese patients, presumably due to increased distribution into fat. Marked increases in distribution (> 100%) have been reported for diazepam and midazolam, and moderate increases (25% to 100%) for alprazolam, lorazepam, and oxazepam. Therapy with benzodiazepines should be administered cautiously in obese patients, with careful monitoring of CNS status. Longer dosing intervals may be appropriate. When dosing by weight, loading doses should be based on actual body weight, while maintenance dose should be based on ideal body weight to avoid toxicity.


  1. "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn (2002):
  2. "Product Information. Valium (diazepam)." Roche Laboratories (2002):
  3. "Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories (2002):
  4. "Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories (2001):
  5. "Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation (2001):
  6. "Product Information. Halcion (triazolam)." Pharmacia and Upjohn (2001):
  7. "Product Information. Dalmane (flurazepam)." Roche Laboratories (2001):
  8. "Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical (2001):
  9. "Product Information. Klonopin (clonazepam)." Roche Laboratories (2001):
  10. "Product Information. Prosom (estazolam)." Abbott Pharmaceutical (2022):
  11. "Product Information. Librium (chlordiazepoxide)." Roche Laboratories (2001):
  12. "Product Information. Doral (quazepam)." Wallace Laboratories (2001):
  13. "Product Information. Versed (midazolam)." Roche Laboratories (2001):
  14. American Medical Association, Division of Drugs and Toxicology "Drug evaluations annual 1994." Chicago, IL: American Medical Association; (1994):
View all 14 references

MKO Troche drug interactions

There are 723 drug interactions with MKO Troche (ketamine / midazolam / ondansetron).

MKO Troche disease interactions

There are 16 disease interactions with MKO Troche (ketamine / midazolam / ondansetron) which include:

Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.